Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CN54gp140 + GLA-AF (Imperial College London, b372a7)
- Development stage
- Phase 1
- Lead developer
- Imperial College London
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
CN54gp140 + GLA-AF is an experimental HIV-1 vaccine candidate consisting of a recombinant trimeric envelope glycoprotein (gp140) and a synthetic adjuvant. The immunogen, CN54gp140, is derived from the HIV-1 clade C strain 97CN54, which represents a predominant subtype in regions heavily affected by the HIV epidemic. The vaccine is formulated with GLA-AF (glucopyranosyl lipid A-aqueous formulation), a synthetic Toll-like receptor 4 (TLR4) agonist that enhances the magnitude and quality of the immune response by promoting innate immune activation. Developed by researchers at Imperial College London, this vaccine candidate is designed to elicit both systemic and mucosal humoral responses, as well as cellular immunity, for the prevention of HIV infection in healthy individuals. It has been evaluated in Phase 1 clinical trials to assess its safety, tolerability, and immunogenicity using various intramuscular prime-boost regimens.
- Other names
- 97CN54gp140CN54 gp140CN-54 gp140CN 54 gp140CN54gp140/GLA-AF
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)gp140 (HIV-1 gp140)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on CN54gp140 + GLA-AF (Imperial College London, b372a7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CN54gp140 + GLA-AF (Imperial College London, b372a7).